Predicting severe infection and effects of hypogammaglobulinaemia during therapy with rituximab in rheumatic and musculoskeletal diseases

ConclusionImmunoglobulin should be monitored at baseline and before each RTX cycle to identify patients at risk of SIEs. Individualised benefit ‐risk assessment should be undertaken in those with lower IgG as this is a consistent SIE predictor and may increase infection profiles when RTX is switched to different therapies.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - May 26, 2019 Category: Rheumatology Authors: Md Yuzaiful Md Yusof, Edward M Vital, Damien M McElvenny, Elizabeth M A Hensor, Sudipto Das, Shouvik Dass, Andy C Rawstron, Maya H Buch, Paul Emery, Sinisa Savic Tags: Full Length Source Type: research